UBS AM’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $559M | Sell |
13,091,481
-422,290
| -3% | -$22.9M | 0.1% | 162 |
|
|
2026
Q1 | $848M | Buy |
13,513,771
+2,576,814
| +24% | +$206M | 0.18% | 108 |
|
|
2025
Q4 | $1.04B | Sell |
10,936,957
-41,428
| -0.4% | -$4.06M | 0.22% | 83 |
|
|
2025
Q3 | $1.07B | Sell |
10,978,385
-1,771,685
| -14% | -$183M | 0.23% | 80 |
|
|
2025
Q2 | $1.37B | Buy |
12,750,070
+1,450,128
| +13% | +$147M | 0.28% | 67 |
|
|
2025
Q1 | $1.14B | Buy |
11,299,942
+460,580
| +4% | +$46.4M | 0.29% | 69 |
|
|
2024
Q4 | $968M | Buy |
10,839,362
+1,709,461
| +19% | +$150M | 0.23% | 78 |
|
|
2024
Q3 | $765M | Sell |
9,129,901
-367,457
| -4% | -$29M | 0.2% | 92 |
|
|
2024
Q2 | $731M | Buy |
9,497,358
+2,173,974
| +30% | +$159M | 0.21% | 87 |
|
|
2024
Q1 | $502M | Sell |
7,323,384
-621,344
| -8% | -$40M | 0.18% | 107 |
|
|
2023
Q4 | $459M | Buy |
7,944,728
+266,715
| +3% | +$14.2M | 0.18% | 115 |
|
|
2023
Q3 | $405M | Buy |
7,678,013
+441,622
| +6% | +$23.2M | 0.18% | 108 |
|
|
2023
Q2 | $362M | Hold |
7,236,391
| – | – | 0.18% | 121 |
|
|
2023
Q1 | $362M | Sell |
7,236,391
-916,301
| -11% | -$43.2M | 0.18% | 121 |
|
|
2022
Q4 | $377M | Buy |
8,152,692
+2,555,480
| +46% | +$111M | 0.2% | 111 |
|
|
2022
Q3 | $217M | Sell |
5,597,212
-52,481
| -0.9% | -$2.11M | 0.12% | 188 |
|
|
2022
Q2 | $211M | Sell |
5,649,693
-17,851
| -0.3% | -$727K | 0.11% | 199 |
|
|
2022
Q1 | $251M | Sell |
5,667,544
-26,416
| -0.5% | -$1.14M | 0.11% | 204 |
|
|
2021
Q4 | $242M | Sell |
5,693,960
-664,364
| -10% | -$27.9M | 0.09% | 232 |
|
|
2021
Q3 | $276M | Sell |
6,358,324
-360,758
| -5% | -$16M | 0.11% | 185 |
|
|
2021
Q2 | $287M | Sell |
6,719,082
-1,480,581
| -18% | -$62.3M | 0.12% | 175 |
|
|
2021
Q1 | $317M | Buy |
8,199,663
+453,168
| +6% | +$17.2M | 0.14% | 150 |
|
|
2020
Q4 | $278M | Buy |
7,746,495
+780,919
| +11% | +$28.1M | 0.13% | 156 |
|
|
2020
Q3 | $266M | Buy |
6,965,576
+231,354
| +3% | +$8.92M | 0.14% | 139 |
|
|
2020
Q2 | $236M | Buy |
6,734,222
+1,404,025
| +26% | +$50.6M | 0.14% | 141 |
|
|
2020
Q1 | $174M | Buy |
5,330,197
+887,942
| +20% | +$34.7M | 0.13% | 165 |
|
|
2019
Q4 | $201M | Buy |
4,442,255
+55,369
| +1% | +$2.32M | 0.12% | 179 |
|
|
2019
Q3 | $179M | Buy |
4,386,886
+215,309
| +5% | +$9.12M | 0.12% | 184 |
|
|
2019
Q2 | $179M | Sell |
4,171,577
-117,665
| -3% | -$4.53M | 0.13% | 173 |
|
|
2019
Q1 | $165M | Buy |
4,289,242
+3,789
| +0.1% | +$145K | 0.12% | 190 |
|
|
2018
Q4 | $151M | Buy |
4,285,453
+182,308
| +4% | +$6.61M | 0.13% | 177 |
|
|
2018
Q3 | $158M | Buy |
4,103,145
+3,487
| +0.1% | +$122K | 0.12% | 200 |
|
|
2018
Q2 | $134M | Sell |
4,099,658
-96,195
| -2% | -$2.9M | 0.1% | 225 |
|
|
2018
Q1 | $115M | Buy |
4,195,853
+492,287
| +13% | +$13.4M | 0.09% | 257 |
|
|
2017
Q4 | $91.8M | Buy |
3,703,566
+31,171
| +0.8% | +$860K | 0.08% | 287 |
|
|
2017
Q3 | $107M | Buy |
3,672,395
+69,263
| +2% | +$1.91M | 0.1% | 234 |
|
|
2017
Q2 | $99.9M | Buy |
3,603,132
+167,326
| +5% | +$4.44M | 0.1% | 246 |
|
|
2017
Q1 | $85.4M | Buy |
3,435,806
+286,705
| +9% | +$6.97M | 0.09% | 260 |
|
|
2016
Q4 | $68.1M | Sell |
3,149,101
-1,924,113
| -38% | -$42M | 0.08% | 279 |
|
|
2016
Q3 | $121M | Buy |
5,073,214
+1,013,316
| +25% | +$24.2M | 0.13% | 171 |
|
|
2016
Q2 | $94.9M | Buy |
4,059,898
+1,042,069
| +35% | +$22.5M | 0.11% | 205 |
|
|
2016
Q1 | $56.8M | Sell |
3,017,829
-62,820
| -2% | -$1.1M | 0.07% | 323 |
|
|
2015
Q4 | $56.8M | Sell |
3,080,649
-677,444
| -18% | -$12.1M | 0.06% | 317 |
|
|
2015
Q3 | $61.7M | Sell |
3,758,093
-402,981
| -10% | -$6.89M | 0.07% | 310 |
|
|
2015
Q2 | $73.7M | Buy |
4,161,074
+45,305
| +1% | +$810K | 0.07% | 301 |
|
|
2015
Q1 | $73.1M | Sell |
4,115,769
-371,014
| -8% | -$5.86M | 0.07% | 307 |
|
|
2014
Q4 | $59.5M | Buy |
4,486,783
+47,529
| +1% | +$608K | 0.06% | 362 |
|
|
2014
Q3 | $52.4M | Sell |
4,439,254
-26,788
| -0.6% | -$337K | 0.05% | 385 |
|
|
2014
Q2 | $57M | Buy |
4,466,042
+90,923
| +2% | +$1.18M | 0.06% | 354 |
|
|
2014
Q1 | $59.2M | Buy |
4,375,119
+189,207
| +5% | +$2.48M | 0.06% | 327 |
|
|
2013
Q4 | $50.3M | Buy |
4,185,912
+149,549
| +4% | +$1.77M | 0.06% | 347 |
|
|
2013
Q3 | $47.4M | Buy |
4,036,363
+47,536
| +1% | +$514K | 0.06% | 335 |
|
|
2013
Q2 | $37M | Buy |
+3,988,827
| New | +$33.8M | 0.05% | 396 |
|
Other funds holding BSX
UBS AM's BSX Position: Q2 2026 in Review
UBS AM reduced its Boston Scientific (BSX) stake by 3.1% in Q2 2026, selling an estimated $22.9M and leaving 13,091,481 shares worth $559M. The position accounts for 0.1% of the portfolio, ranked #162.
UBS AM first reported a position in BSX in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.37B in Q2 2025. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- UBS AM held 13,091,481 shares of Boston Scientific worth $559M as of Q2 2026.
- UBS AM sold 422,290 Boston Scientific shares in Q2 2026, an estimated $22.9M.
- Boston Scientific made up 0.1% of UBS AM's portfolio in Q2 2026, its #162 holding.
- UBS AM first reported a position in Boston Scientific in Q2 2013 and has held it in 53 quarters since.
- UBS AM's Boston Scientific position peaked at $1.37B in Q2 2025.
- 1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.